Page 45 - MemoriaCIBER-2018ENG

biomarker ApoJGly,in a transfer process by means of a spin-off. The clinical utility of other biomarkers such as a panel of miRNAs and sTWEAK is being validated in Line 1.
Line 2 of Programme 4 focussing on
the identification of new biomarkers, coordinated by Dr Jesús Vázquez, concentrates on the identification and small-scale validation of biomarkers in heart failure, ischaemic vascular disease, atrial fibrillation, valve diseases, myocardiopathies and cardiovascular ageing. The projects have an interdisciplinary approach with omic methodologies and imaging and clinical and basic groups. In this line we should highlight the generation of new methodologies of heart imaging, systemic identification
of biomarkers reflecting myocardial or coronary alterations, such as circulating RNAs and proteomic studies on extensive low-risk populations to identify early biomarkers. A representative example of the work done is the study entitled “Prognostic Value of Strain by Tissue Tracking Cardiac Magnetic Resonance After ST-Segment Elevation Myocardial Infarction”, published in the Journal of the American College of
Training Programme
Coordinator: Borja Ibáñez
The CIBERCV Training Programme sets out to train young people to become the cardiovascular researchers of the future in order to improve society’s cardiovascular health through the “Jordi Soler Soler” programme. In the CIBERCV this programme remains the main training endeavour and certain modifications have been brought in to foster training even further in
the framework of collaborative research. This programme is ultimately intended to foster quality translational and collaborative research in the cardiovascular field at the CIBERCV groups through a range of training meant for young people with a research vocation.
Cardiology Cardiovascular Interventions, where it is proven that monitoring tissue in the magnetic resonance technique was able to provide prognostic information shortly after a myocardial infarction, although
this did not substantially improve the reclassification of the risk.
Lastly, the biomarkers programme has, with the cooperation of Dr Domingo Pascual,
got under way the Platform for Precision Cardiovascular Medicine - PMPCV.net. This platform gives information on cohorts of patients and molecular tools, offered to the scientific community by the different groups of the CIBERCV, to facilitate translational research in biomarkers by combining forces. The platform has 63 collections of patients and 21 of animal models, in all over 19,000 samples, covering multiple cardiovascular pathologies. PMPCV.net has intellectual protection and is fully operative, having given rise to an internal call for projects.
The specific objectives of this programme are:
• To structure a procedure for granting subsidies for contracting professionals taking a training plan in translational cardiovascular research in a multidisciplinary setting.
• The contract in research has the aim of promoting capacity-building in research
in a cooperative framework between at least two groups tackling the same problem from different angles. At least one clinical research group and another non-clinical (basic, epidemiological/technological group will take part.
45
CIBERCV | ANNUAL REPORT 2018